Volume 16, Number 2—February 2010
Research
Cost-effectiveness of Pharmaceutical-based Pandemic Influenza Mitigation Strategies1
Anthony T. Newall
, James G. Wood, Noemie Oudin, and C. Raina MacIntyre
, James G. Wood, Noemie Oudin, and C. Raina MacIntyre
Table 2
Base-case economic results per person in the population (healthcare system perspective) of 4 pharmaceutical-based pandemic influenza mitigation strategies*
| Strategy no. | Net cost | Incremental cost | LYS | Incremental LYS | Incremental cost per LYS† |
|---|---|---|---|---|---|
| 1 | 65.88 | – | – | – | – |
| 2 | 82.24 | 16.36 | 0.01803 | 0.01803 | 908 |
| 3 | 100.65 | 18.40 | 0.03501 | 0.01698 | 1,084 |
| 4 | 124.00 | 23.36 | 0.03814 | 0.00313 | 7,458 |
*LYS, life-year saved. Costs and life-years discounted at 5% annually; all costs calculated in 2005 Australian dollars.
†Rounded to the nearest whole dollar.
1This material was compiled before the declaration of pandemic (H1N1) 2009 and concerns stockpiling for a future influenza pandemic.
Page created: December 10, 2010
Page updated: December 10, 2010
Page reviewed: December 10, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.